FDA grants Erasca fast track designation for ERAS-0015 in metastatic pancreatic cancer

Reuters2026/08/24 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Erasca won FDA Fast Track designation for ERAS-0015 to treat metastatic pancreatic adenocarcinoma.
Program supported by Phase 1 data showing 57% uORR at 8 weeks in 2L+ KRAS G12X pancreatic cancer.
Company plans a Phase 3 pancreatic trial. Two potentially pivotal lung cancer studies also planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA grants Erasca fast track designation for ERAS-0015 in metastatic pancreatic cancer

You may also like

Crypto prices